Ovid Therapeutics Stock Forecast, Price & News

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

Is Ovid Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ovid Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View analyst ratings for Ovid Therapeutics or view top-rated stocks.

How has Ovid Therapeutics' stock been impacted by COVID-19?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 17.2% and is now trading at $3.14.
View which stocks have been most impacted by COVID-19.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Ovid Therapeutics.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Wednesday, November, 10th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02.
View Ovid Therapeutics' earnings history.

What price target have analysts set for OVID?

5 equities research analysts have issued 12 month price targets for Ovid Therapeutics' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Ovid Therapeutics' share price to reach $4.50 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Ovid Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:

• Jeremy Max Levin, Chairman, President & Chief Executive Officer
• Jason Tardio, Chief Operating Officer
• Jeffrey A. Rona, Chief Financial, Accounting & Business Officer
• Claude Nicaise, Head-Research & Development
• Julia Tsai, Senior VP-Clinical Development & Medical Affairs

Who are some of Ovid Therapeutics' key competitors?

Some companies that are related to Ovid Therapeutics include uniQure (QURE), Nurix Therapeutics (NRIX), ADVANZ PHARMA (CXRXF), Syndax Pharmaceuticals (SNDX), Gossamer Bio (GOSS), Phibro Animal Health (PAHC), Centessa Pharmaceuticals (CNTA), MacroGenics (MGNX), Kura Oncology (KURA), Endo International (ENDP), PMV Pharmaceuticals (PMVP), Vanda Pharmaceuticals (VNDA), Arcutis Biotherapeutics (ARQT), Tango Therapeutics (TNGX) and Kiniksa Pharmaceuticals (KNSA).
View all of OVID's competitors.

What other stocks do shareholders of Ovid Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $3.14.

How much money does Ovid Therapeutics make?

Ovid Therapeutics has a market capitalization of $213.81 million and generates $12.62 million in revenue each year. The company earns $-81.04 million in net income (profit) each year or $1.79 on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 67 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

Where are Ovid Therapeutics' headquarters?

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at (646) 661-7661 or via email at [email protected].